ReviewWorld journal of urology1996
Molecular biology of prostate cancer.
Review in World journal of urology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 32 citations in OpenAlex.
- Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions.Cancers · 2022Review
- Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Malignant phenotype of PC3 cell line was inhibited by siRNA targeting PAR gene.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2007Article
- Prognostic factors in prostate cancer.Diagnostic pathology · 2006Article
- Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.Oncogene · 2000Article
- Mouse models of prostate cancer.Oncogene · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Carcinoma of the prostate (CaP) is a very prevalent tumor among men. However thus far, relatively little information is known about the molecular mechanisms involved in the development, progression and metastasis of this disease. This article reviews the current state of knowledge of five selected molecular aspects of human CaP: tumor suppressor genes, metastasis suppressor genes and related biological events (allelic loss and DNA methylation), oncogenes (including growth factors and their receptors), the anti-apoptosis gene BCL2, and the human androgen receptor gene (hAR). Alterations of these genes in structure and expression as well as the frequencies of these molecular events are discussed to synthesize an understanding of documented genetic alterations that occur in CaP and their possible relation to the biology of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.